Preferred Label : Imneskibart;
NCIt synonyms : Anti-CD25-IL-2 Monoclonal Antibody AU-007;
NCIt definition : A human immunoglobulin (Ig) G1 monoclonal antibody directed against the CD25 subunit-interacting
domain of the cytokine interleukin-2 (IL-2; IL2), with potential immunomodulatory
activity. Upon administration, imneskibart targets, binds to and blocks the CD25 subunit-interacting
domain of IL-2, thereby blocking the binding of IL-2 to the CD25 subunit (IL-2 receptor
subunit alpha; IL-2Ralpha) of the human trimeric IL-2 receptor (IL-2R) expressed on
the surface of regulatory T-lymphocytes (Tregs), thereby inhibiting IL-2Ralpha-mediated
Tregs activation. This may prevent Treg-mediated immunosuppression. As the ability
of IL-2 to bind to dimeric CD122 (IL-2Rbeta)/CD132 receptor is preserved, imneskibart
promotes immune effector activation by IL-2 via IL-2-mediated signaling through the
dimeric IL-2R. This may active an anti-tumor immune response against tumor cells through
activation of T-lymphocytes, natural killer (NK) cells, and NK T-cells, thereby killing
cancer cells. In addition, by blocking the binding of IL-2 to CD25 expressed on vascular
endothelium and smooth muscle cells and subsequent activation, exacerbation of vascular
leak syndrome (VLS) is prevented. IL-2 binds to the IL-2R dimeric receptor expressed
on CD8 T effector cells, memory T cells, NK cells and NKT cells and is composed of
CD122 and CD132. The IL-2R trimeric receptor expressed on Tregs and vascular endothelium
is composed of CD25, CD122 and CD132.;
UNII : GS5BXY84ZU;
CAS number : 2919583-43-8;
Molecule name : AU 007; AU-007;
NCI Metathesaurus CUI : CL1792022;
Origin ID : C187110;
UMLS CUI : C5706357;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
